NCT03093116 2025-07-10TRIDENT-1Turning Point Therapeutics, Inc.Phase 1/2 Recruiting500 enrolled 2 FDA
NCT02571036 2023-12-13A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced MalignanciesDeciphera Pharmaceuticals, LLCPhase 1 Completed282 enrolled
NCT04697446 2021-08-10External Control, Observational, Retrospective Study Comparing Pralsetinib to Best Available Therapy in Patients With RET-Fusion Positive NSCLCBlueprint Medicines CorporationUnknown279 enrolled
NCT00753415 2015-03-17A Study of V934/V935 Vaccine in Cancer Participants With Selected Solid Tumors (V934-002)Merck Sharp & Dohme LLCPhase 1 Completed37 enrolled 10 charts